

Using the Key Characteristics Framework to Identify Potential Breast Carcinogens



SILENT SPRING INSTITUTE
Researching the Environment and Women's Health


Jennifer Kay, PhD
Silent Spring Institute
Newton, MA
kay@silentspring.org

silentspring.org


Breast Cancer: a public health crisis

- #1 invasive cancer diagnosis in the US and worldwide
- 6x more prevalent than any cancer among men under age 50 in the US
- Rising in rate of diagnosis, esp. in younger women

Incidence in Women ages 20-49



Incidence in Men ages 20-49



Objective

Demonstrate application of the **Key Characteristics framework to identify chemical risk factors** for human chronic diseases using breast cancer as an example

Key Characteristics (KCs) of Carcinogens

Describes features of exposures that cause cancer

Framework for evaluating potential carcinogens based on **mechanistic** effects (which can be measured quickly) rather than cancer (which takes a long time)

For breast cancer, focus on estrogen and progesterone

Key characteristic:

1. Is electrophilic or can be metabolically activated

2. Is genotoxic AKA, damages DNA

3. Alters DNA repair or causes genomic instability

4. Induces epigenetic alterations

5. Induces oxidative stress

6. Induces chronic inflammation

7. Is immunosuppressive

8. Modulates receptor-mediated effects

9. Causes immortalization

10. Alters cell proliferation, cell death, or nutrient supply

Outline

- How we identified breast cancer-relevant chemicals with Key Characteristics
 - Integrate *in vivo* cancer studies (in animals) and *in vitro* molecular effects (in cells) to identify chemical exposures that may increase breast cancer risk
- How we validated our approach
 - Demonstrate that endocrine and genotoxicity data can predict chemicals likely to increase breast cancer risk
- Chemical testing and regulatory decisions: what you need to know
 - The Endocrine Disruptor Screening Program and pesticides

Breast Cancer Etiology




Image credit
Jeff Dixon for
Silent Spring

Breast Cancer-Relevant Exposures

920 chemicals, Ionizing radiation

Rodent Mammary Carcinogens (MCs)

278 chemicals, Ionizing radiation

Databases from IARC, EPA,
National Toxicology Program, and others

Estradiol (E2)/Progesterone (P4) Increases (steroidogens)

346 E2-up, 307 P4-up, 515 total
EPA ToxCast chemical screening

Estrogen Receptor (ER) Activators

267 total
EPA ToxCast chemical screening

Genotoxicity

Databases from US and international agencies

Type of Evidence

Adverse outcome
In animals

Mechanistic
In cells

Mechanistic
Animals and cells

Breast Cancer-Relevant Exposures

920 chemicals, Ionizing radiation

Rodent Mammary Carcinogens (MCs)

278 chemicals

Databases

National Toxicology

Steroidogenic, ER activating, DNA damaging MCs

Dyes (azo-dyes, benzidine-based)
Diethylstilbestrol

Steroidogenic DNA damaging MCs

Chemicals in smoke (PAHs)
Pesticides (Atrazine, malathion, phosmet)
Dyes (p-phenylenediamine)

Progesterone (P4)

307 P4-up

at chemical

Estrogen Receptor (ER)

screening

Well-Known Endocrine Disruptors

Phthalates
Bisphenols
Parabens

Genotoxicity

Databases from US and international agencies


Type of Evidence

Adverse outcome
In animals

Mechanistic
In cells


Mechanistic
Animals and cells

MCs are enriched for BC-relevant KCs




*Fisher exact test for proportion of MCs positive vs. proportion all chemicals positive

MCs are enriched for BC-relevant KCs vs. Non-MCs



*Fisher exact test for proportion of MCs positive vs. proportion non-MCs positive

MCs are more likely to be stronger EDCs




Top EDC score	# Non-MCs	% Non-MCs	# MCs	% MCs	Fold-diff	p-value
High	38	8%	16	21%	2.6	*0.0015^a
Medium	46	10%	12	16%	1.6	0.16 ^a
Low	30	6%	2	3%	0.4	0.29 ^a
Borderline	52	11%	11	14%	1.3	0.44 ^a
None	306	65%	36	47%	0.7	*0.0033^a
Total	472		77			
Trend ^b						*2.1 E-4^b

^aFisher exact test for proportion of MCs positive vs. proportion non-MCs positive

^bTwo-sided Cochran-Armitage trend test for strength of endocrine activity in MCs vs. non-MCs

MCs are more likely to be stronger EDCs and genotoxic



Top EDC score	Gentox	# Non-MCs	% Non-MCs	# MCs	% MCs	Fold-diff	p-value	
High	+	21	6%	13	18%	2.9	*0.0032 ^a	
Medium	+	18	5%	11	15%	2.9	*0.0084 ^a	
Low	+	17	5%	2	3%	0.6	0.55 ^a	
Borderline	+	30	9%	8	11%	1.3	0.51 ^a	
None	+	158	47%	32	45%	1	0.79 ^a	
Trend ^b	+							*0.0012 ^b

Total		336		71			
-------	--	-----	--	----	--	--	--

^aFisher exact test for proportion of MCs positive vs. proportion non-MCs positive


^bCochran-Armitage trend test for strength of endocrine activity in MCs vs. non-MCs

Conclusions

- We identified hundreds of chemicals that could increase breast cancer risk by combining traditional cancer studies with mechanistic data
- Rodent MCs are more likely to increase E2/P4 synthesis, activate the ER, and cause DNA damage vs. non-MCs
- Endocrine activity can flag likely MCs, but *lack of activity does not indicate the chemical is not an MC*
 - E2/P4 steroidogenesis and ER activation are important BC-relevant activities, but there are many others (and most lack methods to screen chemicals for them)
- Our study highlights ways regulatory chemical assessment can be strengthened to better protect human health

Endocrine Disruptor Screening Program: EPA's new proposal to prioritize pesticides


* EPA guideline updated in 1998 for EDC effects, but still missing mammary gland assessment



Coming soon!

We've identified many potential BC hazards – now what?
Further prioritize chemicals for reduction and research!

- Exposure sources
- Biomonitoring and predicted intake levels
- Environmental releases
- Current regulations



Thank you!

Application of the Key Characteristics Framework to Identify Potential Breast Carcinogens Using Publicly Available *in Vivo*, *in Vitro*, and *in Silico* Data

Jennifer E. Kay, Julia Green Brody, Megan Schwarzman, Ruthann A. Rudel

<https://ehp.niehs.nih.gov/doi/10.1289/EHP13233>



We are grateful for funding from Charitable donations to the Safer Chemicals Program at Silent Spring Institute and California Breast Cancer Research Program grant 23QB-1881

kay@silentspring.org | silentspring.org